Compare iShares Core High Dividend ETF (HDV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Summit Therapeutics Inc — how do they compare? iShares Core High Dividend ETF trades at $28.14, while Summit Therapeutics Inc trades at $14.4 (market cap $10.48B). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HDV | SMMT | |
|---|---|---|
52-Week High | $28.36 | $29.32 |
52-Week Low | $23.64 | $13.05 |
Market Cap | — | $10.48B |
Sector | — | Health |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.18, down 0.25% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a 3.0% dividend yield, with recent payouts of $0.19 and $0.09 per share. News coverage highlights HDV's defensive sector focus and competitive expense ratio compared to peers like SCHD and VYM, though some analysts note concentration risk in energy holdings.
Outlook remains cautiously positive given HDV's low volatility and income appeal, but investors face risks from oil price sensitivity and modest dividend growth. The ETF's quality screen provides stability, yet sector concentration may limit upside if energy underperforms.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
